Friday, 11 November 2016

Global Congress

Pharma Microbiology 2017 is scheduled with a vision of promoting the field of Pharmaceutical Microbiology, is going to play its own role in the development of applicability of Pharmaceuticals as there will be an integration of outstanding and ingenious scientists with enthusiastic graduates from all the related fields. Microbiology is the branch of Science, Specifically biology dealing with the study of Micro-organisms, or life too small to be seen with the naked eye.
Set to take place on 19st and 20th June 2017, the 4th annual event in the sell-out Pharmaceutical Microbiology series will bring together all levels of industry professionals, providing essential insights into the latest advancements in practice and technology, developments in regulation and the global harmonisation of evolving microbiology methods.
Join us as we ask questions such as, what are the best approaches in contamination control? Where does microbiological risk assessment interact with HACCP? How do we develop and manage the sterilisation and validation process? When can we use a scoring system to avoid unnecessary microbiological testing? What are the latest approaches to preventing biofilms?
Hear presentations from an array of market leaders such as GSK, Genzyme, Abbott, Med Immune and AstraZeneca, address real world case studies on the benefits and challenges of rapid methods, risk assessments and objectionable organisms.
Pharma/BioTech companies face challenge on how to improve quality of the safety data which is ever increasing in its quantity. Other challenges include managing the dynamic regulatory requirements, etc. which industries and the regulatory authorities face on a regular basis. In this setup, we are looking at communication and networking as important tools that can help industries and departments design new strategies to overcome the several implications.
Top key speakers include:
                    Olivier Chancel, Sterility and Aseptic Process Assurance Expert, Merial Sas – CONFERENCE CHAIRMAN
                    Ruth Daniels, Head of MSAT, Microbiology, Genzyme
                    Sara Gamberini, Molecular Biology Scientist, Merck Serono
                    Hans Noordergraaf, Microbiologist, Abbott Biologicals
                    Thomas Schwartz, Microbiology & Molecular Biology Group Leader, Forschungszentrum Karlsrube Gmbh
                    Tim Eaton, Sterile Manufacturing, Specialist, AstraZeneca
                    Stephen Rawling, Microbiology Team Leader, GlaxoSmithKline

                    Phil Duncanson, Director of QC, MedImmune